CMC Vellore trained BMT specialist — managing the complete transplant pathway for blood cancers, aplastic anaemia and thalassaemia. At CION Cancer Clinics, Banjara Hills, Hyderabad.
BMT is one of the most complex and most misunderstood procedures in haematology. Here's what it actually involves — explained clearly.
Bone marrow transplant — also called stem cell transplant — is a procedure that replaces damaged or diseased bone marrow with healthy blood-forming stem cells. The marrow is the factory inside your bones that produces all blood cells: red cells, white cells and platelets. When this factory is producing abnormal cells (as in leukaemia or MDS) or has stopped working (as in aplastic anaemia), a transplant can replace it entirely.
Despite the word "transplant," BMT is not a surgical procedure. There is no incision. The stem cells are infused through a drip — similar to a blood transfusion — and they find their way to the bone marrow on their own. The intensive part of BMT is the preparation — high-dose chemotherapy (conditioning) given before the infusion to destroy the diseased marrow and suppress the immune system.
Recovery after BMT takes weeks to months. The transplanted stem cells engraft — begin producing normal blood cells — typically within 2–4 weeks. Full immune recovery takes 6–12 months for autologous transplant and 1–2 years for allogeneic. This is when patients are most vulnerable to infection and need close monitoring.
The two main types of BMT are fundamentally different — in procedure, risk, and which conditions they treat.
Your own stem cells — collected, stored, returned
In autologous transplant, stem cells are collected from your own blood before high-dose chemotherapy, frozen and stored, then returned to you after the conditioning. Your own cells rebuild the marrow.
Because your own cells are used, there is no risk of graft rejection or graft-versus-host disease — the main complications of allogeneic transplant. Recovery is typically faster. The trade-off is that autologous transplant has no graft-versus-tumour immune effect.
Donor stem cells — sibling, matched or haploidentical
In allogeneic transplant, stem cells come from a donor — ideally a matched sibling, or if unavailable, an unrelated matched donor or a haploidentical (half-matched) donor such as a parent or child.
Allogeneic transplant carries more risk — graft-versus-host disease (GVHD), where donor cells attack the patient's tissues — but also has a powerful graft-versus-tumour (GVT) effect that helps eliminate residual cancer cells. For many blood cancers and bone marrow disorders, allogeneic BMT offers the best chance of long-term remission or cure.
BMT is not the first treatment for most blood disorders. It's indicated when specific criteria are met — and Dr. Basudev assesses each case carefully before recommending it.
For high-risk AML or ALL in first complete remission, allogeneic BMT significantly improves long-term outcomes compared to chemotherapy alone. For relapsed or refractory leukaemia, allogeneic BMT is often the only potentially curative option.
Autologous BMT after induction chemotherapy remains standard of care for eligible younger patients (typically under 65–70) achieving good response. It deepens the response and extends remission duration. It does not cure myeloma but significantly improves outcomes.
For relapsed or refractory Hodgkin and aggressive non-Hodgkin lymphoma that responds to salvage chemotherapy, autologous BMT (ASCT) offers a chance of long-term remission. For T-cell lymphomas and some high-risk B-cell lymphomas, allogeneic BMT may be considered.
Severe aplastic anaemia in younger patients with a matched sibling donor — allogeneic BMT is the treatment of choice and offers >80% long-term survival. For older patients or those without a matched donor, immunosuppressive therapy is tried first.
For thalassaemia major in young children with a matched sibling donor, allogeneic BMT offers the possibility of cure — eliminating the need for lifelong transfusions. Early transplant in low-risk younger patients has the best outcomes. Learn more →
High-risk MDS — particularly in younger patients — often requires allogeneic BMT as the only potentially curative treatment. The decision depends on IPSS-R score, cytogenetics, response to hypomethylating agents and donor availability.
BMT is a process that takes months from first assessment to recovery. Understanding each stage reduces fear and helps families plan practically.
Dr. Basudev reviews the complete case — diagnosis, stage, previous treatment, response, age, organ function and fitness. The decision whether BMT is indicated, and which type, is made here. This is also when the Tumor Board at CION Cancer Clinics reviews the case collectively.
For allogeneic transplant, HLA typing is done on the patient and potential donors. Siblings are tested first — approximately 25% of siblings are a full match. If no matched sibling is available, unrelated donor registries and haploidentical (parent/child) options are explored.
For autologous BMT, the patient's own stem cells are mobilised with growth factors and collected from the blood (peripheral blood stem cell harvest) over 1–2 days. For allogeneic BMT, the donor undergoes stem cell collection — usually peripheral blood or, less commonly, bone marrow harvest under anaesthesia.
The patient receives high-dose chemotherapy (and sometimes radiation) over 5–7 days immediately before the transplant. This destroys the diseased marrow and suppresses the immune system. This is the most difficult phase — fatigue, nausea, mouth sores and infection risk are highest here.
The stem cells are infused through a central line — similar to a blood transfusion. The infusion takes a few hours. This is not a surgical procedure. The stem cells travel to the bone marrow and begin engrafting over the next 2–4 weeks.
The transplanted cells establish themselves in the marrow and begin producing blood cells. Blood counts are monitored daily. This is when infection risk is highest — patients are in isolation. Engraftment is confirmed when the white cell count recovers consistently.
After discharge, close outpatient monitoring continues. For allogeneic BMT, GVHD prevention and treatment is ongoing. Regular blood counts, disease response assessments and infection monitoring are needed for at least 12 months. Full immune recovery takes 1–2 years for allogeneic BMT.
Yes — and I say this as a haematologist who recommends BMT when it's clearly indicated. BMT is a major intervention with significant risks and a long recovery. Before proceeding, you should be confident that the indication is correct, that the timing is right, and that you've explored whether alternatives might work. Second opinions on BMT recommendations are not just acceptable — they're responsible. If you'd like me to review your case and explain why BMT has been recommended (or whether I agree), please come for a consultation with your full records. That's what I'm here for.
No. Despite the word "transplant," bone marrow transplant is not a surgical procedure. There is no incision, no operation theatre, no general anaesthesia for the transplant itself. The stem cells are infused through a central line — a thin tube placed in a large vein in the chest — in a procedure that takes a few hours, similar to receiving a blood transfusion. The intensive part is the conditioning chemotherapy given in the days before. Many patients are surprised by how undramatic the actual infusion day is after everything that leads up to it.
GVHD — graft-versus-host disease — is a complication of allogeneic BMT where the donor's immune cells recognise the patient's body as foreign and attack it. Acute GVHD affects the skin, gut and liver in the first 100 days. Chronic GVHD can affect multiple organs and persist for years. Mild to moderate GVHD is common and manageable — it's treated with steroids and immunosuppressive drugs. Severe GVHD is a serious complication. Importantly, some degree of graft-versus-host effect also produces a graft-versus-tumour effect that helps control the original cancer. The management of GVHD is a significant part of post-transplant care.
A matched sibling is the ideal donor for allogeneic BMT — but only about 25% of patients have one. If no matched sibling is available, there are other options: a matched unrelated donor (found through bone marrow donor registries), a haploidentical donor (parent, child or half-matched sibling), or in some cases an umbilical cord blood unit. Haploidentical transplant has improved dramatically in recent years and now achieves outcomes comparable to matched unrelated donor transplant in many centres. The absence of a sibling donor does not mean BMT is unavailable.
BMT success rates vary enormously by indication, patient age, disease status at transplant and type of transplant. Autologous BMT for myeloma in first response has treatment-related mortality of less than 3% in good centres, with significant prolongation of remission. Allogeneic BMT for acute leukaemia in first remission has 5-year survival rates of 50–70% depending on disease type and cytogenetics. Aplastic anaemia treated with matched sibling allogeneic BMT has long-term survival above 80% in young patients. The honest answer requires knowing the specific diagnosis, stage and patient profile — which I explain in detail at the consultation.
BMT costs in India vary by centre and transplant type. Autologous BMT typically costs ₹8–15 lakh at specialist centres. Allogeneic BMT costs ₹15–30 lakh or more, depending on whether the donor is a sibling or unrelated, and the duration of hospitalisation. Major centres in Mumbai (Tata Memorial, Kokilaben) and Chennai (Apollo, CMC Vellore) are at the higher end of this range. Hyderabad costs are generally comparable or lower. Most health insurance policies in India cover BMT under critical illness or hospitalisation — though sub-limits and terms vary. At CION Cancer Clinics, our team will help with insurance pre-authorisation and explain the cost structure transparently before you make any decision.
Yes. For thalassaemia major — the severe form requiring lifelong blood transfusions — allogeneic BMT from a matched sibling offers the possibility of cure. The best outcomes are in young children (under 14, ideally under 7), before iron overload from transfusions has caused organ damage. In low-risk young patients, long-term cure rates above 85% are reported. The decision depends on the availability of a matched sibling donor, the child's age and clinical status. This is one of the few situations in haematology where a cure is genuinely achievable. If your child has thalassaemia major and has a sibling, please discuss BMT assessment early — the window for optimal outcomes is a finite one. Learn more about thalassaemia →
Recovery timelines vary by transplant type. For autologous BMT, hospitalisation is typically 2–4 weeks, and most patients can return to normal activities within 2–3 months, though full energy recovery may take 6–12 months. For allogeneic BMT, hospitalisation is 4–6 weeks or longer, outpatient monitoring continues intensively for 3–6 months, and full immune recovery takes 1–2 years. During this period, patients need to avoid infections, take immunosuppressive medications and attend regular follow-up appointments. Work or school return is typically 3–6 months for autologous, 6–12 months for allogeneic BMT — depending on the individual's recovery and the original disease.
Dr. Basudev Pokhrel at CION Cancer Clinics, Hyderabad, is experienced in the complete BMT pathway — from initial indication and donor matching through to post-transplant care and monitoring. He completed his Post-Doctoral Fellowship in Clinical Haematology at CMC Vellore, one of Asia's most respected haematology and transplant programmes. Available at ANR Centre, Banjara Hills, Hyderabad. Contact +91 9063490160.
For some patients, yes. Allogeneic BMT offers the best chance of long-term disease-free survival for several leukaemia subtypes — particularly high-risk AML and ALL in first remission. The graft-versus-leukaemia (GVL) immune effect is a significant part of why allogeneic BMT works — the donor immune system continues to suppress residual leukaemia cells after transplant. Long-term disease-free survival (often used as a surrogate for cure) of 50–70% is achievable in optimal cases. But "permanent cure" is language I use carefully — long-term follow-up is always needed, and some patients relapse even after transplant. What I can tell you is that for the right patient in the right disease state, allogeneic BMT offers the best available chance of sustained remission.
If disease returns after BMT, options depend on the disease type, the type of transplant and the timing of relapse. For allogeneic BMT, donor lymphocyte infusion (DLI) can be used to boost the graft-versus-tumour effect. A second transplant may be considered in selected patients. For many relapsed post-transplant situations, newer immunotherapy agents and targeted drugs have created salvage options that didn't exist a decade ago. I will not minimise the seriousness of post-transplant relapse — it is a difficult situation. But it is not always without options.
Many health insurance policies in India cover BMT under critical illness or hospitalisation benefits. Coverage terms vary significantly — some policies have sub-limits on transplant procedures, waiting periods for critical illness, or requirements for specific network hospitals. At CION Cancer Clinics, our team assists with insurance documentation and pre-authorisation. Before your consultation, check whether your policy covers BMT specifically, whether the hospital is in-network, and what the sub-limit is. Bring your policy document and we'll help you understand the coverage.
Bring all your existing reports and previous treatment records. Dr. Basudev will review the complete case and give you a direct, honest assessment of whether BMT is indicated for your situation.